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Stem cell synthesized extracellular matrix (ECM) may serve as a replacement for 
current bone grafting techniques. The overall goal of this thesis is to quantify the 
osteoinductivity of the ECM produced by human amniotic fluid stem cells (AFS cells), 
compare it to that of human mesenchymal stem cells (MSC), and assess its potential for 
use in bone tissue engineering therapies. 
 Each stem cell type was cultured in osteogenic media to produce the ECM, which 
was then decellularized via freeze/thaw cycling and DNase treatment. The success of the 
decellularization was confirmed with live/dead staining and DNA quantification.  
 A series of in vitro studies were performed to evaluate the characteristics of the 
ECM relevant to a bone tissue engineering therapy.  Reseeded MSCs were able to attach 
to and proliferate on both ECM types in both 2D and 3D culture.  In 2D, cells cultured on 
both ECM types showed increased levels of calcium deposition. Additionally, cells 
cultured on the MSC ECM showed increased alkaline phosphatase activity. A synergistic 
effect on osteogenic differentiation was observed when the osteoinductive factor 
dexamethasone was added to the culture. In 3D, both ECM types increased the 
mineralized matrix production of reseeded MSCs. The AFS ECM had a greater effect 
than the MSC ECM. 
 When ECM was used to treat a rat femoral segmental defect in vivo, it was found 
that each ECM type increased the rate of bridging of the defect when compared to 
collagen coated scaffolds. However the ECM did not have a significant effect on the 







 Bone defects may occur due to trauma, osteolytic disease, congenital 
malformations, or tumor resection. The current methods of treating such defects, 
autografts and allografts, both have their associated shortcomings. As a result, tissue 
engineers seek to develop a bone graft substitute that possesses the advantages of the 
autograft and the allograft without the drawbacks. Stem cells have the ability to 
differentiate into osteoblasts, making them a possibility for a bone tissue engineering 
treatment. However, there are several obstacles associated with implanting live cells 
including immunogenicity and cell survival. An alternative use of stem cells would be to 
use them to synthesize an extracellular matrix (ECM) which then may be used as a bone 
graft alternative. Studies have shown that the ECM synthesized by mesenchymal stem 
cells (MSCs) that are differentiating down the osteogenic pathway has the ability to 
induce osteogenic differentiation in other non-differentiated MSCs.[1] Amniotic fluid 
stem cells (AFS cells) are another stem cell type that possess high osteogenic potential. 
This thesis seeks to determine the osteoinductivity of AFS cell synthesized ECM, explore 
its effectiveness for healing a bone defect, and compare its overall potential as a bone 
graft substitute to that of MSC synthesized ECM. 
Background 
 Bone injuries are a common problem, with approximately 6 million fractures 
occurring annually in the United States.[2]  The process of bone healing consists of three 
 2
stages: an initial inflammatory response, the formation of a fracture callus, and the 
remodeling of the callus to restore the bones original shape and strength. With adequate 
vascularity, the presence of osteoinductive factors, the availability of osteoprogenitor 
cells, and mechanical stability, bone has the unique ability to regenerate itself without 
scar formation.[3, 4, 5] However in some cases these conditions are not met and surgical 
intervention is necessary to achieve proper healing.  In such cases bone grafts are 
required to treat the bone defect. An estimated 500,000 bone-grafting operations are 
performed each year in the United States to treat patients with nonunions or large 
defects.[6]  These large defects may be the result of a variety of causes including 
traumatic injury, congenital malformations, osteolytic disease, tumor resection, or soft 
tissue damage (spinal fusions). The graft aids in the healing of these defects by providing 
osteoinductive and angiogenic growth factors, a source of cells capable of osteogenesis, 
and/or a structural matrix to impart mechanical stability.[7] 
 The current gold standard for treatment of large osseous defects is the autograft, 
where bone is harvested from another location within the patient, usually the iliac crest, 
and delivered to the injury site.  There are many features of autografts that make them 
desirable for treating bone defects: they are osteoconductive and osteoinductive, they 
contain cells capable of osteogenesis, and they are from the patients own body and 
therefore avoid immune rejection.[5]  However, three characteristics of autografts limit 
their effectiveness. First, because the iliac crest is the only significant source of autograft 
tissue, the amount of tissue that can be harvested is limited in quantity. Second, in many 
cases the harvesting procedure can result in pain and/or morbidity at the donor site. 
Finally, autografts do not provide structural integrity to the injury site.[8]  An alternative 
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treatment that avoids these drawbacks is the allograft, which involves harvesting bone 
from a cadaver for the grafting material. This technique has the advantage of providing 
more graft material and structural support to the defect site. However the allograft has its 
own drawbacks including lack of viable cells, risk of disease transmission,  poor 
remodeling, and inconsistencies between donors. This leads to a 25% clinical failure rate 
and 30-60% overall complication rate. [9, 10, 11]   
 Given the limitations associated with the current treatments, there is a clear need 
for a more refined approach to the grafting of large bone defects. The field of tissue 
engineering aims to develop biological substitutes to restore, maintain, or improve tissue 
function. To do so, it makes use of principles from both engineering and the life sciences. 
[12, 13]  The overall goal of bone tissue engineering research is to develop a bone graft 
substitute that possess all the benefits of both the autograft and the allograft, without the 
associated limitations.[14] Successful bone regeneration requires a vascular supply, 
osteoinductive factors, and a source of cells capable of differentiating into osteoblasts. 
Tissue engineers attempt to supply one or more of these aspects to stimulate the body’s 
natural healing response. Many of these approaches involve the use of a matrix material 
or scaffold that may serve several purposes: it may act as an osteoconductive surface to 
facilitate bone growth, a structural support to provide mechanical integrity at the defect 
site, a delivery vehicle to bring other factors to the injury site, or a combination of the 
three.[3] However, the use of a matrix material or scaffold alone has proven to be 
inadequate when attempting to restore function to a large bone defect.[15]  
 Growth factor proteins are widely studied for their use in a variety of tissue 
engineering applications. Each protein has highly specific actions, lending to their 
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usefulness.[16] Bone morphogenetic proteins (BMPs) are one family of growth factors of 
particular interest in bone tissue engineering.[17, 18, 19] First defined is 1965 by Marshal 
Urist, they have been shown to induce bone formation in both ectopic and orthotopic in 
vivo models. [20, 21, 22] Although the delivery of BMPs alone has been shown to heal a 
segmental defect, it takes a very high dose to do so, which risks the formation of cyst-like 
bone voids.[19]  As a result, several methods are being developed to administer growth 
factors in a controlled fashion, releasing a lower dose that is sustained over a longer 
period of time.[23, 24]  However, even with a safer, more efficient delivery method, the 
high cost of producing such growth factors may ultimately limit their clinical use. 
 Cell-based therapies comprise another promising line of research in orthopaedic 
tissue engineering. Cells produce the mineralized matrix that constitutes the extracellular 
component of bone, and therefore are ultimately responsible for bone repair. Therapies 
comprised of scaffolds and/or growth factors alone rely on native cells from within the 
host to migrate to the injury site to initiate injury repair. However in smokers, elderly 
patients, and patients receiving chemotherapy or radiation treatment, the endogenous 
osteoprogenitor cell population may be compromised, making such treatments 
ineffective.[25]  The lack of a live cell population is thought to be one of the reasons 
allografts have poor remodeling and higher failure rates.[26]  To account for these 
deficiencies, many cell-based therapies attempt to deliver live cells that are capable of 
osteogenesis to the defect site. A large number of cells are needed for repair of a large 
defect. Fully differentiated osteoblasts are therefore not an attractive option due to the 
large amount of time it would take to obtain an appropriate number of cells via in vitro 
expansion. Instead, cell-based therapies center on the use of stem cells. Stem cells have 
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two major advantages: they are highly proliferative and they can undergo osteogenic 
differentiation to produce bone.[27] 
 The source of stem cells remains a critical issue in tissue engineering. Cells from 
different sources have different characteristics and capabilities.[28, 29] Mesenchymal 
stem cells (MSCs) are the most studied cell source for orthopaedic tissue engineering. 
First isolated from bone marrow, MSCs were found to adhere to tissue culture plates, 
form spindle shapes similar to fibroblasts, and proliferate in colonies.[30, 31] Although 
there is some heterogeneity within this cell population, as evidenced by the various 
names given to subtypes over the years including bone marrow stromal cells, mesodermal 
progenitor cells, and connective tissue progenitors, they generally share the 
characteristics as being adherent and forming colonies on tissue culture plates, having a 
spindle shape, and having the ability to differentiate into one or more of the connective 
tissues.[32, 33, 34] With the proper chemical and mechanical stimuli, MSCs have shown 
the ability to differentiate into several different cell types including adipocytes, myocytes, 
chondrocytes, tenocytes, hepatocytes, epithelial cells, neural cells, and most importantly 
for bone tissue engineering, osteoblasts.[35, 36] Osteogenic differentiation can be 
induced by adding dexamethasone, ascorbic acid, and an inorganic phosphate source to 
the media.[37]  Since their initial discovery in bone marrow they have also been found in 
other tissue types such as adipose tissue, synovium, trabecular bone, human umbilical 
cord, teeth, and lung. [38, 39] 
 Many studies have been done in several models to investigate the use of MSCs in 
a bone graft substitute. Bruder led some of the first studies to explore using bone marrow 
derived MSCs to heal a critically sized bone defect. In the groups initial study they 
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seeded cultured-expanded autologous rat MSCs on cylindrical hydroxyapatite/tricalcium 
phosphate (HA/TCP) scaffolds and implanted them in an 8 mm critically sized femoral 
segmental defect in adult rats. They found that the scaffolds containing MSCs showed 
better healing and a greater bone fill percentage than empty scaffolds or scaffolds 
containing unprocessed bone marrow.[40] A similar study was then done on a larger 
scale, implanting autologous MSCs on HA/TCP scaffolds into a 21 mm critically sized 
canine femoral segmental defect. This large animal model yielded similar results to the 
rat model, with the MSC loaded scaffolds showing significantly better healing than 
empty scaffolds or empty defects.[41] The group then turned to an allogeneic cell source 
to determine if the results would be similar to an autologous source. Human MSCs were 
seeded on HA/TCP scaffolds and implanted into 8 mm femoral segmental defects in 
athymic rats. The cell loaded constructs showed increased healing in comparison to 
empty constructs, with bone fill similar to that seen in the autologous cell scaffolds of the 
previous study. Additionally, mechanical testing was performed on the excised limbs, 
with the femurs receiving MSC loaded scaffolds showing greater strength than the femurs 
that received  scaffolds alone.[42] Other groups have had success using MSCs derived 
from both bone marrow and adipose tissue to heal bone defects in a variety of small and 
large animal models. Bone marrow and adipose derived MSCs delivered on apatite-
coated polylactic-co-glycolic acid (PLGA) scaffolds healed a critically-sized mouse 
calvarial defect.[43]  Enhanced bone formation was observed when autologous MSCs 
expanded on coral granules were implanted into a sheep metatarsal defect.[44]  
 Although the immunogenicity of MSCs is still a topic of controversy, several 
studies suggest that MSCs may avoid allogeneic immune rejection via multiple 
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mechanisms.[45] MSCs do not appear to possess MHC class II proteins, which are potent 
alloantigens. This may account for some of their hypoimmunogenicity.[46, 47, 48] Other 
evidence suggests that MSCs can avoid immune rejection by maintaining dendritic cells 
in an immature state.[49]  The immature dendritic cells can then silence T cells by either 
expanding regulatory T cell populations or by deletion.[50] In addition to regulating T 
cells indirectly through dendritic cells, evidence also exists that suggests that MSCs have 
the ability to regulate T cells via a direct method.[51] Finally, MSCs may create an 
immunosuppressive local environment via the secretion of soluble factors. These factors 
include prostaglandins, interleukin-10, and indoleamine 2,3,-dioxygenase. [52] Although 
some data conflicts these claims, it is thought that the observed differences are due to 
different cell sources and techniques used to isolate the MSCs.[52] 
 Despite the osteogenic capabilities and apparent hypoimmungenicity of MSCs, 
there are some drawbacks associated with this cell source. A cell-based clinical treatment 
will most likely require a very large number of cells to effectively heal a large bone 
defect. However, the concentration of MSCs in healthy tissue is relatively low, and 
becomes even more scarce as patients age, in smokers, or in patients receiving radiation 
or chemotherapy treatments.[25] In addition, their in vitro expansion capacity is limited 
as they may lose multilineage differentiation capabilities due to telomere shortening.[32] 
As a result of these limitations, an alternative stem cell source is desirable.  
 Amniotic fluids stem cells (AFS cells) may offer a promising alternative to MSCs 
in tissue engineering.[53]  Amniocentesis is routinely performed during the second 
trimester of pregnancy to test the fetus for chromosomal abnormalities or infections.[54]  
A needle is inserted through the mother's abdominal wall into the uterus and amniotic sac 
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and approximately 20 ml of amniotic fluid are extracted. Fetal cells are then isolated from 
the fluid to make various diagnoses. Researchers have found multipotent progenitor cells 
within this cell population.[55, 56]  These cells can be isolated using ligand stem cell 
factor, which binds to the membrane receptor c-kit found on the cells. AFS cells have 
shown the ability to differentiate into cells from all three embryonic germ layers, 
including adipogenic, osteogenic, myogenic, endothelial, neuronal and hepatic lineages. 
Additionally, they can expand without feeders, are non-tumorigenic, and maintain their 
normal karyotype through over 250 population doublings. [56] When exposed to 
osteogenic media containing dexamethasone, ascorbic acid 2-phosphate, and β-glycerol 
phosphate, the AFS cells express alkaline phosphatase, osteocalcin, and precipitate 
calcium indicating osteogenic differentiation. In 3-D culture on poly-ε-caprolactone 
(PCL) scaffolds the cells produced extensive amounts of mineralized matrix as measured 
by microcomputed tomography (microCT). Additionally, AFS cells that had been 
precultured on PCL scaffolds in osteogenic media and then implanted ectopically in 
athymic rats produced a significant amount of mineralized matrix in vivo.[57] 
Unpublished data from our lab further indicates that although AFS cells show a delay in 
mineralized matrix production when compared to MSCs, they ultimately show greater 
osteogenic potential.  
Several possible approaches exist for using stem cells in tissue engineering. One 
possibility is that they may be delivered in an undifferentiated state with differentiation 
cues coming from the construct or the injury site.[40] A second approach involves 
exposing the cells to differentiation factors in vitro prior to implantation so that they are 
in the process of differentiation prior to delivery.[57, 58, 59]  Stem cells may also be 
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altered via gene therapy to express certain factors to aid in bone repair, such as 
BMPs.[60]  Finally, the cells may be used to synthesize an extracellular matrix (ECM) 
product in vitro which is then decellularized and implanted into the injury site to promote 
healing.[1, 61] Because the last approach does not involve the implantation of live cells, 
it avoids many of the complications of the other cellular therapies including 
immunogenicity of the cells, preservation of the cells for an off-the-shelf therapy, and 
maintaining cell survival upon implantation. 
 ECM consists of a complex milieu of biologic factors and structural proteins. Not 
only does it provide a support structure for adherent cells, but it also acts as a localized 
reservoir for secreted growth factors that can be released at a later time to affect cellular 
behavior.[62]  ECM can be decellularized through either mechanical or chemical 
methods, or through a combination of the two.[63, 64]  Acellular matrices have been 
produced from a variety of tissues including intestine, bladder, skin, and heart valves.[65, 
66, 67, 68]  Evidence suggests that the ECM retains its bioactivity following the 
decellularization process.[69, 70]   
Several studies have been done by the Mikos group to evaluate the use of MSC 
synthesized ECM in bone tissue engineering.  In one study, MSCs were seeded on 
titanium fiber scaffolds and cultured in osteogenic media. The ECM was then 
decellularized via freeze-thaw cycling, reseeded with MSCs, and cultured in media 
lacking the osteogenic stimulus dexamethasone. The ECM was found to induce 
osteogenic differentiation in the reseeded MSCs, as evidenced by their increased levels of 
alkaline phosphatase and calcium in comparison to MSCs seeded on the titanium 
scaffolds alone. Additionally, when dexamethasone was added to the media a profound 
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synergistic effect was observed: the cells seeded on ECM with dexamethasone had much 
higher alkaline phosphatase and calcium levels than cells cultured on ECM without 
dexamethasone or cells cultured on titanium scaffolds alone with dexamethasone.[1]  In a 
similar study, it was found that the ECM influenced the cells at the level of gene 
expression, causing an upregulation of genes associated with osteogenesis, coupled with 
a downregulation of genes associated with chondrogenesis.[71]  These results may 
suggest that the ECM provides an optimal microenvironment for osteogenic 
differentiation. In addition to the observed osteoinductivity, the group also found the 
matrix to have some angiogenic properties. When constructs were implanted 
intramuscularly in rats, a greater number of blood vessels were observed in constructs 
that contained ECM than titanium scaffolds alone.[61]   
Because differentiating stem cells create an environment that is more dynamic 
than that of mature osteoblasts, the ECM they create may contain a different composition 
of molecules that are beneficial to bone repair. The ECM composition may differ 
between the different stem cell types as well. AFS cells are initially in a more primitive 
state than MSCs. Although this causes them to take longer to differentiate, the longer 
differentiation time may allow them to produce greater amounts of growth factors. The 
ECM may promote improved osteogenic differentiation, cell attachment, proliferation, or 
angiogenesis.  A stem cell synthesized ECM treatment for bone tissue engineering 
applications would have advantages over current bone graft techniques, as it circumvents 
having to harvest an autograft from the patient while also avoiding the risk of disease 




The overall goal of this thesis is to quantify the osteoinductivity of the ECM 
produced by human AFS cells, compare it to that of MSCs, and assess its potential for 
use in bone tissue engineering therapies.  Due to the primitive state of stem cells, they 
may produce ECM that is more osteoinductive than currently used grafting treatments 
with less limitations. This research is novel as it explores a promising regenerative 
medicine technique for bone. It is significant because it seeks to establish a bone tissue 
engineering approach with many advantages over current grafting methods.  
Aim 1: 
 Examine and quantify the osteoinductivity of ECM produced by osteogenically 
induced human AFS cells and compare it to that of human MSCs in vitro.   In order to 
assess the osteoinductivity of the ECM, it was first isolated from the cells that 
synthesized it. In a series of studies, both AFS cells and MSCs were cultured in 
osteogenic differentiation media for varying lengths of time to generate ECM on 2D 
culture dishes. The matrix was then decellularized using freeze-thaw cycling, and 
reseeded with cells. Human MSCs were utilized for all of the reseedings, as they are 
more representative of the cell type that would migrate to the injury site in vivo. The cells 
were cultured further in media containing supplements necessary for osteogenesis but no 
osteoinductive factors (supplemental media), as well as full osteogenic media containing 
dexamethasone (complete media) to examine synergistic effects. Assays were performed 
on the cultures at various time points to analyze them for factors associated with 
osteogenic differentiation.  These included alkaline phosphatase, calcium, and DNA 
content.  
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Further studies evaluated the osteoinductivity of the ECM in 3D. Both cell types 
were cultured in osteogenic differentiation media on 3D PCL scaffolds, decellularized at 
various time points, reseeded with MSCs, and cultured further in both supplemental and 
complete osteogenic media. Microcomputed tomography was used to quantitatively 
monitor mineralization over time. The amount, distribution, and morphology of the 
ECM-induced mineralized matrix production were compared between the two cells types 
and between different time points of ECM production. Finally, the effect of the ECM on 
cellular attachment and proliferation was evaluated. PCL scaffolds containing ECM 
produced by either AFS cells or MSCs were loaded with MSCs and then measured for 
DNA content at various time points to determine both how many cells attached to the 
ECM constructs initially, and how rapidly those cells divided. It was hypothesized that 
the ECM produced by the human AFSs would be osteoinductive, and that the degree of 
osteoinductivity would be greater than that of the MSC-synthesized ECM due to the 
difference in the initial maturity levels of the cells. 
Aim 2: 
 Evaluate the bone regenerative potential of ECM produced by osteogenically 
induced AFS cells and compare it to that of MSCs.   In order to evaluate the bone tissue 
engineering potential, the ECM was utilized in a challenging critically-sized segmental 
defect model. Decellularized scaffolds containing ECM were created as in the 3D in vitro 
study, with the optimum ECM production time determined in Aim 1. The scaffolds were 
then implanted into critically-sized femoral segmental defects in nude rats. MicroCT and 
high resolution x-ray images were taken at four week intervals up to twelve weeks in 
order to monitor and quantify mineral formation and defect union. The study compared 
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the AFSC-synthesized ECM constructs to MSC-synthesized ECM constructs and empty 
PCL scaffolds. The comparisons were made based on mineral formation and bridging of 
the defect. It was hypothesized that the mineralization and bridging of defects containing 
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CHAPTER 2 
IN VITRO CHARACTERIZATION OF STEM CELL SYNTHESIZED 
EXTRACELLULAR MATRIX FOR BONE TISSUE ENGINEERING 
 
Introduction 
 Several in vitro methods exist for evaluating the efficacy of potential bone tissue 
engineering therapies.  Many of these techniques can be applied to 2D cell cultures. One 
of the most common ways of evaluating osteogenic differentiation in 2D is to quantify 
the alkaline phosphatase activity and calcium content of the culture. Alkaline phosphatase 
is a hydrolase enzyme that is expressed in preosseous cells.[1] During the differentiation 
of MSCs down the osteogenic pathway, alkaline phosphatase activity will usually peak 
after 1 to 2 weeks of culture and then taper off.[2] As the cells differentiate further, they 
will begin to calcify the extracellular matrix to produce a bone-like ECM. The calcium 
content of the matrix typically increases from 2 weeks of culture onward.[2] In the 2D 
studies, each of these parameters were quantified at different time points to monitor the 
osteogenic differentiation of the reseeded cells.  
 In addition to inducing osteogenic differentiation, the acellular ECM may have 
other effects that are beneficial in bone tissue engineering applications. One such aspect 
that can be evaluated in 2D in vitro culture is the effect of the ECM on the proliferation 
of reseeded MSCs. If the ECM induces a stronger proliferative effect, it would be 
beneficial as there would then be more cells to differentiate. In contrast, if the ECM 
suppresses proliferation it could have a negative effect by limiting the amount of cells 
capable of osteogenesis. To determine the effect of the ECM on the proliferation of the 
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reseeded MSCs, a PicoGreen assay was used to quantify DNA, which is indicative of 
relative cell number, at various time points.  
 While 2D studies provide an easy, inexpensive way to evaluate effects of the 
acellular ECM on reseeded cells, they can not exclusively determine the potential of a 
bone tissue engineering therapy. Bone repair takes place in a large, dynamic, complex 3D 
environment. 3D in vitro studies can provide a more accurate representation of this 
environment for the evaluation of possible therapies. Several different scaffold types have 
been used for 3D culture of cells.[3]  In these studies, cells were seeded on medical grade 
PCL scaffolds for the preculture ECM synthesis period. The scaffolds were biopsy 
punched out of a sheet created by fused deposition modeling with a 0, 60, 120 degree 
strut orientation and 85% porosity. These scaffolds have several characteristics that make 
them beneficial in the evaluation of bone tissue engineering therapies. They are highly 
porous to allow cell attachment and mass transport, they have good mechanical stability, 
and due to their highly organized structure there is less scaffold variability influencing 
the observed effects.[4]  Scaffolds were coated with type I collagen to create a bioactive 
surface and improve cell attachment.[5, 6] When large 3D scaffolds are cultured in static 
conditions, there is a tendency for mineralization to occur only at the periphery of the 
scaffold, leaving the core empty. Therefore, scaffolds in this study were cultured on 
rotary rocker plates to improve mass transport within the scaffold. This has been shown 
to induce a more even distribution of mineral throughout the scaffold.[5]   
 To analyze osteogenic differentiation in the 3D samples, microCT analysis was 
performed. The microCT takes a series of x-ray scans that are then used to construct a 3D 
image of the scaffold. By picking a threshold value that excludes the scaffold material, 
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cells, and soft tissue, the mineralized matrix produced by the cells could be isolated and 
quantified. These scans were taken at several time points to monitor the production over 
time. Multiple scans can safely be made of each scaffold, as the microCT has been shown 
to have no significant effect on cell mediated mineralization potential.[5, 7, 8]  In 
addition to the microCT scans to evaluate osteoinductivity, the DNA was also quantified 
for the 3D scaffolds using the PicoGreen assay to assess the effect of the 3D ECM on cell 
attachment and proliferation.  
 Two different media types were used to culture the reseeded MSCs. The first was 
“osteogenic media”, which is supplemented with dexamethasone, β-glycerol phosphate, 
and ascorbic acid 2-phosphate. Of these three components, the dexamethasone is the 
primary osteoinductive agent, with the other two components supplementing the 
differentiating cells, but not inducing osteogenic differentiation themselves. If 
dexamethasone is removed from this media, cells cultured on tissue culture plastic will 
not osteogenically differentiate in significant numbers as they lack an osteoinductive 
agent. However, if another osteoinductive agent such as BMP is added to the culture they 
will experience differentiation. Cells were cultured with osteogenic media on the ECM to 
determine if there was a synergistic effect as has been seen in other studies.[9] The 
second media type used was referred to as “supplemental media”, which is similar to the 
osteogenic media but does not contain dexamethasone. It therefore will not induce 
osteogenic differentiation itself. This media was used to test if the ECM itself was 
osteoinductive. 
 In order to isolate the effect of the acellular ECM on the reseeded MSCs, it is 
imperative that the ECM be fully decellularized. Several chemical agents have been used 
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to decellularize matrices. These include acid/alkaline treatments such as peracetic acid, 
ionic detergents including sodium dodecyl sulfate, non-ionic detergents like Triton-X 
100, or enzymatic treatments such as trypsin and DNase.[10]  While these techniques are 
able to decellularize tissue, they usually require several long incubation periods and 
washes. Additionally, they may inadvertently remove desirable ECM components. As an 
alternative, mechanical techniques such as freeze/thaw cycling and lyophilization can be 
applied to disrupt cellular membranes.[11] While these can successfully devitalize a 
tissue, they do not completely remove cellular debris. In previous studies evaluating the 
osteoinductivity of MSC synthesized ECM, freeze/thaw cycling was used as the 
decellularization technique. This method was initially attempted in this study. However, 
it was found that a significant amount of DNA remained entrapped within the ECM 
following decellularization, making it impossible to accurately assess cell attachment and 
proliferation. The freeze/thaw cycling was therefore followed up with DNase treatment to 
fully decellularize the ECM. 
 The goal of this aim was to use in vitro techniques to characterize the effect of 
stem cell synthesized ECM on reseeded MSCs. More specifically, it set out to compare 
AFS cell synthesized ECM to MSC synthesized ECM in terms of its capability as a bone 
tissue engineering treatment.  It was hypothesized that the ECM produced by the human 
AFS cells would be osteoinductive, and that the degree of osteoinductivity would be 
greater than that of the MSC-synthesized ECM due to the difference in the initial 




Materials and Methods 
Stem Cell Isolation and Culture 
 The Institute for Regenerative Medicine at Wake Forrest University graciously 
provided the human AFS cells used in these studies. Amniotic fluid was obtained via 
amniocentesis, and stem cells expressing the membrane receptor c-kit were isolated via 
immunoselection using an antibody for CD117.[12]  The cells were then expanded at 
37°C, 5% humidified CO2 in α-MEM supplemented with 15% FBS, 2 mM L-glutamine, 
100 units penicillin, 100 µg streptomycin (all Invitrogen, Carlsbad, Ca), 18% Chang B, 
and 2% Chang C (Irvine Scientific, Santa Ana, CA), which will be referred to as “AFS 
expansion media”.[12] Media was changed every 3 to 4 days during culture. Cells were 
received at passage 14 and were then passaged another 2 to 3 times before use, reaching 
no more than 70% confluence on each expansion. For storage, cells were frozen in AFS 
expansion media supplemented with 5% DMSO. For use, cells were rapidly thawed at 
37°C and seeded on 150mm culture plates (BD Falcon, San Jose, CA) in AFS expansion 
media at a concentration of 100,000 cells per plate. Cells were harvested once they 
reached 70% confluence (approximately 1 week) by treating them with 0.25% trypsin-
EDTA (Invitrogen).  
 Human MSCs were obtained from Tulane Center for Gene Therapy through the 
NIH-funded center for preparation and distribution of adult stem cells (2P40RR017447-
06).  2 ml bone marrow aspirates were taken from the iliac crest of healthy human 
donors.[13, 14]  Cells were isolated from these aspirates and expanded on tissue culture 
dishes (Nuncleon ∆ surface, Thermo Fisher, Rochester, NY) at 37°C, 5% humidified CO2 
in α-MEM medium supplemented with 17% FBS (Atlanta Biologicals), 2mM L-
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glutamine, 100 units penicillin, 100 µg streptomycin (all Invitrogen), which will be 
referred to as “MSC expansion media”.  Media was changed every 3 to 4 days during 
culture. Cells were not allowed to reach more than 70% confluence. For storage, cells 
were frozen in α-MEM supplemented with 30% serum and 5% DMSO.  For use, cells 
were rapidly thawed at 37°C and seeded on 100 mm culture plates (Nuncleon ∆ surface, 
Thermo Fisher, Rochester, NY) in MSC expansion media. After 24 hours the cells were 
treated with 0.25% trypsin-EDTA to remove them from the plate, counted, and reseeded 
at a density of 50 cells/cm2 on 150 mm culture plates (Nuncleon ∆ surface, Thermo 
Fisher, Rochester, NY) in MSC expansion media. Cells were harvested once they reached 
70% confluence (approximately 7-10 days) by treating them with 0.25% trypsin-EDTA.  
Osteogenic Differentiation and Decellularization Process 
 To differentiate the MSCs and the AFS cells down the osteogenic lineage, the 
cells were cultured in MSC expansion media further supplemented with 1 µM 
dexamethasone, 3 mM β-glycerol phosphate, 50 µg/ml ascorbic acid 2-phosphate, and 
50ng/ml thyroxine (all Sigma, St Louis, Missouri), which will be referred to as 
“osteogenic media”. [15, 16]  The media was changed every 3 to 4 days during the 
differentiation period. Once the cells had been cultured for the desired time period, the 
ECM was decellularized using a combination of mechanical and chemical means.[9, 10, 
11]  First, the cells were subjected to rapid freeze/thaw cycling to disrupt the cellular 
membranes. For the 2D studies on tissue culture plates, the cultures were frozen in a -80 
°C freezer for 20 minutes and then thawed at room temperature for 20 minutes. This 
process was repeated three times. For the 3D studies on PCL scaffolds, the constructs 
were placed in 1.5 ml micro-centrifuge tubes. The tubes were then immersed in 
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isopropanol at -80 °C for 20 minutes to freeze the constructs, followed by immersion in 
37 °C water to thaw. This was repeated 3 times. The freeze/thaw cycling was followed 
with DNase treatment (Worthington Biochemical Corporation, Lakewood, NJ) to remove 
some cellular debris. The ECM was exposed to 1 mg/ml DNase for 30 minutes at 37 °C, 
followed by rinsing in PBS three times.  
 Successful decellularization was confirmed via two methods. First, a PicoGreen 
DNA quantification kit (Invitrogen) was used to measure the amount of DNA within the 
PCL scaffolds both before and after the decellularization process. Scaffolds were treated 
with 0.125 mg/ml Proteinase K (Worthington Biochemical Corporation) for 24 hours at 
45 °C, followed by 2 hours at 60 °C to digest the ECM and cell membranes and release 
the DNA into solution. Samples were then diluted 1:20 in Tris-EDTA assay buffer. 
Lambda DNA standards were produced from 1 µg to 1 ng. 100 µl from each sample were 
added to 100 µl of PicoGreen working solution in black 96-well plates. After a 5 minute 
room temperature incubation period, the fluorescence was read at an excitation of 485 nm 
and an emission of 535 nm (Perkin-Elmer HTX 7000 fluorescent plate reader, Waltham 
MA) (n=4).  
 In addition to quantifying the DNA within the scaffolds, a Live/Dead 
Viability/Cytotoxicity kit (Molecular Probes, Invitrogen) was used to assess 
decellularization throughout the scaffolds. Scaffolds were washed three time in PBS, 
incubated for 45 minutes in 4 µM Ethidium homodimer-1 and 4 µM Calcein AM, and 
washed three additional times in PBS. Scaffolds were then viewed using a confocal 
microscope (LSM 510 UV, Carl Zeiss, Thornwood, NY). Images were taken at random 
of the top, bottom, side, and interior (by making a longitudinal cut) of the scaffolds. In 
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addition to images of the scaffolds pre and post decellularization, images were also made 
of scaffolds that had been reseeded with MSCs to examine the efficiency and distribution 
of the reseeding. 
2D Studies 
 For 2D studies, MSCs or AFS cells were seeded on 24-well culture dishes at a 
concentration of 10,000 cells/cm2 in MSC expansion media. After three days the media 
was switched over to osteogenic media, which was then changed every 3 to 4 days. At 3 
weeks from the initial seeding the cultures were decellularized as described, leaving the 
intact ECM. MSCs were then reseeded onto the ECM and cultured in the appropriate 
media until samples were collected for analysis. 
DNA Quantification 
 A PicoGreen DNA quantification assay was performed to assess how effectively 
the reseeded MSCs populated and proliferated on the ECM in 2D. ECM was produced as 
described and reseeded with MSCs. The reseeded samples were cultured in MSC growth 
media, changed every 3 to 4 days. Two cellular groups and two acellular control groups 
were included: MSCs cultured on MSC synthesized ECM, MSCs cultured on AFS cell 
synthesized ECM, MSC synthesized ECM without reseeded cells, and AFS cell 
synthesized ECM without reseeded cells. Samples were collected in 500 µl of 0.05% 
Triton-X100 (Sigma-Aldrich, St Louis, MO) in PBS at 24 hours, 1 week, 2 weeks, and 3 
weeks following reseeding. DNA was quantified using the PicoGreen kit as previously 




Alkaline Phosphatase Activity 
 Alkaline phosphatase content was assessed in 2D culture using an assay to 
measure its activity. Samples were prepared as previously stated. Groups included ECM 
synthesized by each cell type reseeded with MSCs and then cultured in either osteogenic 
media or “supplemental media”, which consists of  MSC expansion media further 
supplemented with 6 mM β-glycerol phosphate, 50 µg/ml ascorbic acid 2-phosphate, and 
50ng/ml thyroxine (no dexamethasone). Additionally, two control groups consisted of 
ECM produced by each cell type and reseeded with human embryonic kidney epithelial 
cells (HEK cells) in osteogenic media. These cells have been shown to be incapable of 
mineralized matrix production, and therefore served as a cellular negative control.[17]  
Both cell types and media conditions were also analyzed on tissue culture plastic for 
comparison. A summary of the experimental groups can be seen in Table 2.1. Samples 
were collected in 500 µl of 0.05% Triton-X100 in PBS at 24 hours, 1 week, 2 weeks, and 
3 weeks. Alkaline phosphatase activity was determined by incubating the samples with p-
Nitrophenyl phosphate (pNPP) and measuring how much p-Nitrophenol (pNP) was 
produced via the enzyme hydrolyzing the phosphate group off of the pNPP. pNP 
standards were created varying from 800 to 12.5 µM. 50 µl of each sample were added to 
50 µl of working solution containing 20 mM pNPP and incubated at 37 °C for 1 hour. 
Absorbance was determined at 405 nm with a plate reader (PowerWave XS, BioTek,  
Winooski, VT)  (n=6). 
Calcium Quantification 
 The amount of calcium present within the ECM produced by the reseeded cells 
was assessed using a calcium quantification assay. Groups, culture conditions, and 
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sample collection times were the same as used for the alkaline phosphatase assay. 
Samples were collected in 1 N acetic acid and incubated at room temperature overnight. 
They were then diluted 1:20 in 1 N acetic acid. 25 µl of diluted sample were added to 300 
µl of calcium reagent (Arsenazo III, Diagnostic Chemicals Limited) in clear 96-well 
plates and incubated for 30 seconds at room temperature. Absorbance was determined at 
615 nm with a plate reader (n=6). 
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Table 2.1:  Summary of experimental groups for 2D calcium and alkaline phosphatase 
assays. 
 
Group Matrix Type Cell Type for Reseed Culture Media 
1 AFS-synthesized MSC Osteogenic 
2 MSC-synthesized MSC Osteogenic 
3 Collagen MSC Osteogenic 
4 AFS-synthesized MSC Supplemental 
5 MSC-synthesized MSC Supplemental 
6 Collagen MSC Supplemental 
7 AFS-synthesized HEK Osteogenic 
8 MSC-synthesized HEK Osteogenic 






 For 3D studies, cells were seeded on PCL scaffolds and cultured in a dynamic 
environment. Using fused deposition modeling, 100 mm x 100 mm by 9 mm thick sheets 
of PCL were created with a 0, 60, 120 degree strut orientation and 85% porosity.[4] A 6 
mm biopsy punch was used to create cylindrical scaffolds from the sheet measuring 6 
mm diameter by 9 mm thick (Figure 2.1). Scaffolds were incubated at 37 °C for 1 hour in 
5 M NaOH to increase surface roughness.[5]  They were then rinsed 5 times in deionized 
water and sterilized by immersion in ethanol, which was allowed to evaporate overnight. 
 A collagen network was created within the pores of the scaffold in order to 
improve cell attachment.[5, 6] 100 parts of 1.5 mg/ml type I rat tail collagen in 0.05% 
acetic acid was combined with 9 parts of 71.2 mg/ml sodium bicarbonate solution. 220 µl 
of the solution was place into a 6 mm diameter by 10 mm deep cylindrical mold. 
Scaffolds were then inserted into the mold, immersing them in the collagen solution. The 
collagen was allowed to gel for 30 minutes at room temperature. The constructs were 
frozen in the mold at -80 °C for 1 hour and then lyophilized overnight. For cell seeding 
and culture, the scaffolds were removed from the mold and inserted into holders 
consisting of a ¾ inch diameter Teflon disk with 4 stainless steel pins forming a 
perimeter around the scaffold (Figure 2.2). The holders were designed to maintain the 
orientation of the scaffold during dynamic culture. The scaffolds and holders were then 
placed in 12-well tissue culture plates (Nunc, low cell binding surface). 
 Two million cells were resuspended in 200 µl of the appropriate expansion media 
and added drop-wise to the top surface of the collagen coated scaffolds. The media was 
readily absorbed by the collagen throughout the scaffold. The scaffolds were then 
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incubated for 1 hour at 37 °C to allow for cellular attachment. 4 ml of expansion media 
were then added to each well and the constructs were cultured at 37 °C. After 3 days the 
constructs were switched over to osteogenic media, which was then changed every 3 to 4 
days, and cultured on an orbital shaker (Belly Button® orbital shaker, 7.5 rpm, minimal 
pitch, Stovall, Greensboro, NC) to improve mass transport within the inner regions of the 
constructs.[5, 18]  
 After the indicated preculture period, the ECM was decellularized via freeze/thaw 
cycling and DNase treatment as described. To facilitate reseeding throughout the 3D 
scaffolds, they were lyophilized following the decellularization treatment to remove 
liquid within the scaffold and allow media containing cells to spread throughout. The 
ECM containing scaffolds were then reseeded with MSCs using the same procedure as 
the initial seeding.  
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Figure 2.1:   MicroCT images of the side and top views of a 6 mm diameter by 9 mm 













Figure 2.2:   Diagram of Teflon disk with stainless steel pins used to hold scaffolds 




 Mineralized matrix production within the constructs was assessed using 
microcomputed tomography (microCT). Table 2.2 summarizes the experimental groups 
for the 3D mineralization study. ECM was synthesized by each cell type for either 4 or 8 
weeks for comparison between different preculture periods. Reseeded MSCs were 
cultured in either osteogenic or supplemental media. As controls, MSCs were cultured on 
collagen coated scaffolds in each media type and HEK cells were cultured on each matrix  
type. Scaffolds were microCT scanned at 0, 4, and 8 weeks in a sterile scanning chamber. 
They were scanned at a 38 µm voxel resolution (VivaCT scanner, Scanco Medical, 
Switzerland). Scans were evaluated at a threshold of 80, a filter width of 1.2, and a filter 
support of 2 (n=6).[5]   
Attachment and Proliferation 
 Cell attachment efficiency on 3D ECM constructs was evaluated via DNA 
quantification. Constructs were prepared and reseeded with MSCs as in the 3D 
mineralization study. 1 day and 1 week after reseeding scaffolds were collected, treated 
with Proteinase K, and analyzed using a PicoGreen DNA quantification kit as previously 
described. 
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Table 2.2:  Summary of experimental groups for 3D mineralization on PCL scaffolds. 
 
Group Matrix Type Matrix Preculture Period 
Cell Type for 
Reseed Culture Media 
I AFS-synthesized 4 Weeks MSC Osteogenic 
II AFS-synthesized 8 Weeks MSC Osteogenic 
III MSC-synthesized 4 Weeks MSC Osteogenic 
IV MSC-synthesized 8 Weeks MSC Osteogenic 
V Collagen N/A MSC Osteogenic 
VI AFS-synthesized 4 Weeks MSC Supplemental 
VII AFS-synthesized 8 Weeks MSC Supplemental 
VIII MSC-synthesized 4 Weeks MSC Supplemental 
IX MSC-synthesized 8 Weeks MSC Supplemental 
X Collagen N/A MSC Supplemental 
XI AFS-synthesized 4 Weeks HEK Osteogenic 
XII AFS-synthesized 8 Weeks HEK Osteogenic 
XIII MSC-synthesized 4 Weeks HEK Osteogenic 
XIV MSC-synthesized 8 Weeks HEK Osteogenic 




 All statistical analysis was performed using GraphPad Prism (GraphPad Software, 
La Jolla, CA). For comparison between experimental groups and time points, an analysis 
of variance was performed with Tukey post hoc analysis. Differences were considered 
statistically significant if p<0.05.  
Results 
Decellularization 
 The effectiveness of the decellularization process was evaluated via DNA 
quantification assays and live/dead staining. Figure 2.3 displays the results of the DNA 
quantification assay. The decellularization process reduced the quantity of DNA within 
the scaffold to less than 10% of the amount prior to decellularization. Images of the 
live/dead stained scaffolds were taken both pre (Figure 2.4.A-D) and post 
decellularization (Figure 2.4.E-H). Prior to decellularization, extensive numbers of live 
(green) cells were seen attached throughout the scaffold, while very few dead (red) cells 
were present. After the decellularization process virtually all cells within the scaffold 
were dead. Additional images were taken of a decellularized scaffold reseeded with 
MSCs (Figure 2.4.I-L).  In addition to the dead cells left over from the decellularization 




Figure 2.3:    DNA content of scaffolds pre and post decellularization. Decellularization 
process significantly decreased cellularity of the scaffolds (n=4). * p<0.0001, error bars 





Figure 2.4:   Confocal microscopy images of scaffolds pre decellularization (A-D), post 
decellularization (E-H), and reseeded with MSCs after decellularization (I-L). Live cells 
appear green and dead cells appear red. Images were taken of the exterior of the scaffolds 
at the top (A,E,I), bottom (C,G,K), and side (D,H,L), as well as of the interior by cutting 




 Results from the DNA quantification of MSCs cultured on 2D ECM can be seen 
in Figure 2.5. Cells were able to attach to and proliferate on ECM synthesized by both 
cell types. By 1 week there was an approximately 5 fold increase in the quantity of DNA 
present in the groups that had been reseeded with MSCs. This value held steady through 
two weeks and then decreased by week 3. At the time of reseeding and at 1 week, there 
was a significant difference between the DNA content of the AFS cell synthesized ECM 
that had been reseeded and MSC synthesized ECM that had been reseeded. However, 
there was also initially a significant difference between the acellular control groups. The 
initial difference between the reseeded MSC and AFS cell ECMs may therefore be due to 
differing initial amounts of DNA left over from the decellularization process. In fact, at 
the time of reseeding the difference in DNA quantity between the reseeded and acellular 
AFS ECM groups was about equal to the difference between the reseeded and acellular 
MSC ECM groups, and approximately equivalent to the 20,000 cells that had been 
reseeded. However, by the 3 week time point the DNA quantity in the reseeded AFS 
ECM group had decreased further than that of the reseeded MSC ECM group. Both 
acellular control groups contained a significant amount of DNA at the beginning of the 
culture period. This was most likely due to DNA that was left over from the 
decellularization process, as the values quickly subsided to near zero by week 1 as the left 
over DNA diffused out of the ECM.  
 The alkaline phosphatase activity of the MSCs cultured on each ECM type can be 
seen in Figure 2.6. In osteogenic media, the MSCs cultured on MSC ECM showed a peak 
in alkaline phosphatase activity at 1 week, followed by a decline. In contrast, MSCs 
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cultured on tissue culture plastic showed a gradual increase in alkaline phosphatase 
activity through 3 weeks. The value of alkaline phosphatase activity at the peak for the 
MSC ECM group was higher than any value reached by the group seeded on tissue 
culture plastic. The alkaline phosphatase activity of the MSCs seeded on AFS ECM never 
reached a value above the background level. Similar results were observed for cells 
cultured in the supplemental media. When comparisons were made between MSCs 
cultured on MSC ECM in osteogenic versus supplemental media, it was found that at 
weeks 0, 2, and 3 there was no significant difference. However, at the peak expression at 
1 week the osteogenic group showed greater activity. Activity of the HEK cell control 
groups remained at the background level throughout the culture period. 
 Results of the calcium assay can be seen in Figures 2.7 and 2.8. The data is 
normalized by the initial amount of calcium from the preculture period to display only the 
calcium produced after reseeding. Figure 2.7 makes comparisons between the MSCs in 
osteogenic media, MSCs in supplemental media, and HEK cells for each ECM type. For 
the cells seeded on the AFS ECM, the MSCs in osteogenic media contained more 
calcium than the HEK cell group at 2 weeks, while the supplemental group did not reach 
a difference until 3 weeks. For the MSC ECM groups, the MSCs cultured in both 
osteogenic and supplemental media showed greater calcium content than the HEK cell 
group from week 1 onward. For cells cultured on tissue culture plastic, the calcium 
content for the osteogenic media group reached significance at 3 weeks, while the 
supplemental group did not reach a level of significance within the time period of this 
study.  
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 Figure 2.8 uses the same data to make comparisons between the various matrix 
groups for the same media conditions. In osteogenic media, the MSC ECM group shows 
a difference compared to the no ECM group at 1 week, while the AFS ECM group does 
not show a difference until 2 weeks. However, there was no difference between the AFS 
ECM group and the MSC ECM group at any time with osteogenic media. In 
supplemental media, both AFS ECM and MSC ECM groups showed a difference 
compared to the no ECM group by 2 weeks. Additionally, the MSC ECM group had a 
higher calcium content than the AFS ECM group at this time, although this difference 
subsided by 3 weeks. 
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Figure 2.5:   DNA quantification of MSCs cultured on AFS cell or MSC synthesized 
matrix.(n=6). * p<0.05, # p<0.05 compared to week 0, $ p<0.05 compared to week 3. 









Figure 2.6:    Alkaline phosphatase activity for MSCs cultured on ECM in A) osteogenic 
media, B) supplemental (n=6). * p<0.05 compared to MSCs on tissue culture plastic, # 
p<0.05 compared to MSCs on AFS cell synthesized ECM, $ p<0.05 compared to other 
time points, & p<0.05 compared to week 1, ! p<0.05 compared to week 3. Error bars are 






Figure 2.7:   Calcium content for cells cultured on A) AFS cell synthesized ECM, B) 
MSC synthesized ECM, C) tissue culture plastic (n=6). * p<0.05 compared to MSCs in 







Figure 2.8:   Calcium content for MSCs cultured on ECM in A) osteogenic media, B) 
supplemental (n=6). * p<0.05 compared to MSCs on MSC synthesized ECM, # p<0.05 
compared to MSCs on AFS cell synthesized ECM. Error bars are ± standard error. 
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3D Studies 
 The 3D mineralization data is displayed in Figures 2.9-12. The data is normalized 
by the initial mineral volume produced during preculture to represent only the 
mineralization formed post-reseeding.  Figures 2.9-11 compare mineral volume amounts 
between MSCs in osteogenic and supplemental media and HEK cells cultured on each 
ECM type and preculture time (4 and 8 weeks). For the MSC synthesized ECM, with 
both preculture periods the osteogenic group contained more mineralized matrix than the 
HEK cell group. Additionally on 4 week precultured ECM the osteogenic group also 
showed greater volume than the supplemental group. For the AFS ECM, with both 
preculture periods the osteogenic and supplemental groups both contained more mineral 
than the HEK cell group at 4 weeks. At 8 weeks, the osteogenic media group with 4 week 
precultured ECM also showed a greater amount than the corresponding supplemental 
media group. For cells cultured on collagen coated scaffolds, at 8 weeks the supplemental 
group was greater than the HEK cell group, while the osteogenic group was greater than 
both the HEK cell group and the supplemental group. 
 Figure 2.12 uses the same data to makes comparisons between the various matrix 
types and preculture periods.  In osteogenic media, at 4 weeks both AFS ECM groups 
had greater mineralized matrix content than the MSC ECM or collagen groups. 
Additionally, at this time the 8 week preculture AFS group had a greater volume of 
mineral than the 4 week preculture AFS group. By 8 weeks, both MSC groups caught up 
to the 4 week preculture AFS group. Both the 4 week preculture groups were greater than 
the collagen group. The 8 week preculture AFS group remained greater than all other 
groups at this time. For the supplemental media, the differences observed were the same 
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as with the osteogenic media at the same time point. However, at 8 weeks, while the 8 
week preculture AFS group remained greater than all other groups, the 4 week preculture 
AFS group was greater than the 4 week preculture MSC group and collagen group, and 
there is no difference between the collagen group and either MSC group. Figures 2.13 
and 2.14 show representative microCT images of each group at the 4 and 8 week time 
points respectively.  
 From the DNA quantification assay, it was found that the attachment efficiency 
for reseeded MSCs differed between the ECM groups and the collagen scaffolds (Figure 
2.15). While approximately 95% of the 2 million cells that were reseeded onto the 
collagen scaffolds attached, only about 25 to 50% of the cells reseeded on the various 
ECM types attached. However, the number of cells on each scaffold increased 
significantly during the first week of culture, and by 1 week there was no difference in 






Figure 2.9: 3D mineralized matrix volume produced by cells cultured on MSC 
synthesized ECM with preculture periods of A) 4 weeks  B) 8 weeks (n=6). * p<0.05 
compared to supplemental media, # p<0.05 compared to HEK cells, $ p<0.05 compared 






Figure 2.10: 3D mineralized matrix volume produced by cells cultured on AFS cell 
synthesized ECM with preculture periods of A) 4 weeks  B) 8 weeks (n=6). * p<0.05 
compared to supplemental media, # p<0.05 compared to HEK cells, $ p<0.05 compared 




Figure 2.11: 3D mineralized matrix volume produced by cells cultured on collagen 
coated scaffolds (n=6). * p<0.05 compared to supplemental media, # p<0.05 compared to 








Figure 2.12: 3D mineralized matrix volume produced by MSCs cultured in A) osteogenic 
media  B) supplemental media (n=6). * p<0.05 compared to collagen coated scaffolds, # 
p<0.05 compared 4 week precultured MSC synthesized ECM, $ p<0.05 compared to 8 
week precultured MSC synthesized ECM, & p<0.05 compared to 4 week precultured 
AFS cell synthesized ECM. Error bars are ± standard error. 
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Construct Type Osteogenic Media Supplemental Media HEK Cells 
4 Week AFS ECM 
  
8 Week AFS ECM 
  
4 Week MSC ECM 
   
8 Week MSC ECM 
   
Collagen Coated 
Scaffolds 
   
 
Figure 2.13:    MicroCT images of 3D constructs 4 weeks following reseeding. Images 
are representative of the average value of mineral volume for each group at the 4 week 
time point. The columns show in order: reseeded MSCs cultured in osteogenic media, 
reseeded MSCs cultured in supplemental media, and reseeded HEK cells cultured in 
osteogenic media. Scale bars are 1 mm.  
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Construct Type Osteogenic Media Supplemental Media HEK Cells 
4 Week AFS ECM 
  
 
8 Week AFS ECM 
   
4 Week MSC ECM 
  
 
8 Week MSC ECM 
   
Collagen Coated 
Scaffolds 
   
 
Figure 2.14:    MicroCT images of 3D constructs 8 weeks following reseeding. Images 
are representative of the average value of mineral volume for each group at the 8 week 
time point. The columns show in order: reseeded MSCs cultured in osteogenic media, 
reseeded MSCs cultured in supplemental media, and reseeded HEK cells cultured in 





Figure 2.15:   Cell attachment proficiency for MSCs reseeded onto decellularized ECM 









Figure 2.16:    DNA content of decellularized ECM constructs 1 day and 1 week 





 This aim set out to use in vitro analysis techniques to characterize stem cell 
synthesized ECM for use in bone tissue engineering applications. The success of these 
studies depended foremost on the effectiveness of the decellularization procedure and the 
ability of the MSCs to repopulate the acellular ECM. The DNA quantification data 
displays that the decellularization process was successful in devitalizing most, if not all of 
the cells within the ECM. In 2D without reseeded cells, the quantity of DNA quickly 
went to zero by one week in culture as DNA entrapped within the matrix left over from 
decellularization diffused out. In 3D, the decellularization process removed over 90% of 
the DNA from the ECM. Even the small amount of DNA left over was most likely not 
associated with live cells, but rather free DNA entrapped within the matrix similar to the 
2D study. The conclusions were further confirmed by the live/dead staining. Although the 
scaffolds were saturated with live cells before decellularization, after freeze/thawing and 
treatment with DNase virtually none could be found in any region of the scaffold.  
 Not only was the decellularization process successful, but results also showed that 
MSCs were able to repopulate and proliferate on the acellular ECM. Live/dead staining 
of reseeded scaffolds showed live MSCs throughout the scaffold. The distribution of the 
cells on the scaffold was important because they were seeded from the top only. Their 
presence at the bottom and within the interior of the scaffold indicates that they were 
either able to diffuse through the pores within the scaffold or migrate along the surface of 
the ECM. Cells were able to proliferate on both AFS and MSC synthesized ECM. In both 
the 2D and 3D cultures, the DNA content increased approximately 5 fold after 1 week. In 
2D this was a saturation point, with the cells maintaining that number for another week 
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before decreasing in DNA content at 3 weeks. For the 3D culture, the collagen coated 
scaffolds initially had a higher number of cells attach. However, the DNA content of 
these scaffolds at 1 week was approximately the same as the ECM coated scaffolds. 
Therefore, the cells actually proliferated less during the first week of culture on the 
collagen than on the various ECM types. However, from this data it could not be 
determined whether the ECM had a greater proliferative effect on the cells, or if the cells 
were hitting a saturation point on the scaffolds by the 1 week time point.  
 Previous work has been done to evaluate the osteoinductivity of MSC-synthesized 
ECM.[9, 19, 20, 21, 22] It was observed that culturing MSCs on the MSC-synthesized 
ECM resulted in increased alkaline phosphatase activity and calcium content, indicative 
of osteogenic differentiation.[9] Similar results were observed in these studies. 
Additionally, a synergistic effect was previously observed when adding dexamethasone 
to the culture media for the cells cultured on the ECM.[9]  This effect was also observed 
in the alkaline phosphatase activity data in these studies. The cells cultured in 2D on the 
AFS cell synthesized ECM did not perform as well as the MSC ECM cultured cells in 
these measures of osteogenic differentiation. Although the calcium content did increase 
for these cells in both the osteogenic and supplemental media, it was at a slower rate than 
the cells cultured on MSC ECM. Additionally, the AFS ECM groups did not show 
significant levels of alkaline phosphatase activity. These results suggest that with 3 weeks 
of 2D preculture, ECMs synthesized by both cell types have osteoinductive capabilities 
as indicated by the increased calcium content in comparison to cells cultured on tissue 
culture plastic. Additionally, MSC synthesized ECM acts as a better osteoinductive agent 
than AFS cell synthesized ECM, as measured by the alkaline phosphatase activity.  
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 In 3D the opposite effect was observed. At each time point, preculture period, or 
media condition, the cells cultured on the AFS cell synthesized matrix either matched or 
exceeded the cells cultured on MSC synthesized matrix in terms of volume of mineral 
produced. Within the AFS ECM groups, the 8 week preculture period resulted in the 
reseeded cells producing more mineralized matrix than their 4 week preculture 
counterparts. The difference in mineral volume between the 8 week preculture AFS ECM 
and MSC ECM was greater than the difference between the 4 week preculture groups. 
These results suggest that in 3D with preculture periods of 4 weeks or longer, AFS cell 
synthesized ECM induce more mineralized matrix formation than MSC synthesized 
ECM, and that longer preculture periods result in a greater effect, at least up until 8 
weeks.  
 In the 2D studies, the MSC synthesized ECM had a greater osteoinductive effect 
on reseeded MSCs. However, in the 3D studies, the AFS cell synthesized ECM induced 
greater mineralized matrix production. One possible explanation for this discrepancy may 
be a difference between 2D and 3D culture. The ECM may induce osteogenic 
differentiation by altering the micro-environment of the cells. If the micro-environment is 
different between 2D versus 3D culture, this may account for the different effects on the 
cells. If this is the case, the AFS cell synthesized ECM would make the more likely 
candidate for a bone tissue engineering therapy, as bone repair takes place in a 3D 
environment and the AFS ECM performed better in 3D. 
 A second explanation for the different effects seen could be related to the 
preculture period. With the shorter preculture period the MSC ECM showed greater 
osteoinductivity. However, with a longer preculture period the AFS ECM induced greater 
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mineralized matrix production. This difference may be related to the initial maturity level 
of the cells. The MSCs are initially a more differentiated cell type. Because of this, with 
shorter preculture times the MSCs become further differentiated and the ECM is more 
specific towards the osteogenic lineage compared to the AFS ECM. However, with more 
preculture, the AFS have more time to differentiate and the ECM they produce becomes 
more mature. This may cause the ECMs effect on the mineralized matrix production of 
reseeded cells to become more pronounced. If this is the case, AFS cell ECM precultured 
for a longer period of time would be more ideal for a bone tissue engineering therapy. 
 In this aim, the decellularization procedure of freeze/thaw cycling followed by 
DNase treatment was found to successfully decellularize the stem cell synthesized 
extracellular matrix. MSCs were able to then repopulate and proliferate on this matrix. In 
2D, ECM that was synthesized by MSCs had a greater osteoinductive effect on reseeded 
MSCs. However, in 3D, AFS cell synthesized matrix proved to cause greater mineralized 
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CHAPTER 3 
IN VIVO EVALUATION OF THE BONE REGENERATIVE POTENTIAL  
OF STEM CELL SYNTHESIZED EXTRACELLULAR MATRIX 
 
Introduction 
 In vitro studies provide an efficient, cost-effective method of characterizing a 
potential therapy. However, short of clinical trials in humans, the best way to evaluate the 
true usefulness of a therapy is through in vivo animal models. There are a complex array 
of factors that influence an engineered construct at the site of tissue repair. These include 
mechanical and chemical stimuli, migrating cells, angiogenesis, mass transport 
limitations, and immune responses. While in vitro experiments may be designed that 
mimic some of these factors, it is the culmination of all of these components that controls 
the healing response induced by the therapeutic agent. While the anatomy and physiology 
of other animals differs from that of humans, animal models still provide a much closer 
approximation of the clinically relevant environment than even the most complex of in 
vitro models can come close to achieving. Because of this, animal studies are considered 
the ultimate preclinical test for any emerging therapy.  
 Several animal models exist for the evaluation of potential bone tissue 
engineering therapies. The simplest of these models is the ectopic model, which involves 
implanting the construct within the subcutaneous space.[1] This model is useful for 
showing osteoinduction by the potential therapeutic agent, as there are no native 
osteoinductive factors at the implantation site. Additionally, it is efficient as it allows 
several groups to be compared within each animal. However, this model is not directly 
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clinically relevant as it does not involve the healing of a bone defect.  The calvarial defect 
model involves creating a defect within the top of the skull. These defects have the 
advantages of being easy to create and requiring no fixation device.[2] However, this 
model is limited by a high rate of spontaneous healing due to the high vascularity of the 
region, as well as the presence of an excellent source of osteoprogenitor cells within the 
surrounding periosteum and cranial bone marrow.  A more challenging model is 
preferred to allow for better discernment between groups. Long bone defects have been 
created in the radius, ulna, tibia, and femur of several animal types, including mice, rats, 
rabbits, and dogs.[3]  Rodent long bone defects have been used extensively in preclinical 
animals studies due to their short times to skeletal maturity, limited housing 
requirements, and low cost when compared to larger animals. Of the various long bone 
defect types, the femoral segmental defect provides perhaps the most challenging model 
due to its lack of proximity to other bones that may contribute vascularity or 
osteoprogenitor cells to the osteotomy.  
 In this study, an 8 mm rat femoral segmental defect model was used. Previous 
studies have utilized a 5 mm defect model to test potential therapies. However, with this 
smaller defect size, spontaneous healing was found to occur even without treatment.[4, 5]  
As a result, the more challenging 8 mm defect model was established.[6, 7] Spontaneous 
healing will not occur with this defect size, meeting the criteria of a critically sized 
defect.[8]  Defects  in this study were stabilized using a custom modular fixation plate 
made of polysulfone (Figure 3.1). The low radiopacity of these plates creates a window 
for x-ray and microCT scanning of the defect to noninvasively monitor and quantify 
healing over time. 
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 The goal of this aim was to evaluate the bone regenerative potential of ECM 
produced by osteogenically induced AFS cells and compare it to that of MSCs. It was 
hypothesized that the mineralization and bridging of defects containing ECM constructs 
would be greater than that of the empty scaffolds. 
Materials and Methods 
Scaffold Preparation 
 Scaffolds were prepared in the same manner as the in vitro 3D studies. In brief, 
cylindrical scaffolds measuring 6 mm diameter by 9 mm thick were created from PCL 
sheets. Scaffolds were treated with 5 M NaOH to roughen the surface, sterilized via 
ethanol evaporation, and coated with lyophilized collagen to improve cell attachment.[9] 
Two million cells (either AFS cells or MSCs) were seeded on the scaffolds and cultured 
in osteogenic media for 8 weeks to produce ECM. The 8 week preculture time was 
chosen based on the in vitro studies, as this time showed the greatest mineralized matrix 
formation in 3D culture. After the preculture period, the scaffolds were decellularized via 
freeze/thaw cycling and DNase treatment and lyophilized to create greater porosity for 
cellular infiltration. Three groups were included in the in vivo study: AFS cell 
synthesized ECM, MSC synthesized ECM, and collagen coated scaffolds as a control 
(n=10) 
Femoral Segmental Defect Surgery 
 All animals studies were performed within the guidelines of protocol A06020 
approved by the Institutional Animal Care and Use Committee at the Georgia Institute of 
Technology. All surgical procedures were performed under general anesthesia 
(Isoflourane) using aseptic techniques. Femoral segmental defects were created 
 64
bilaterally in 13 week old athymic female nude rats (Charles River Laboratories, 
Wilmington, MA) . Prior to the procedure, the incision site was shaved and scrubbed, 
alternating chlorhexidine with isopropyl alcohol. An incision was made over the anterior 
length of the femur. Blunt dissection of the quadriceps muscle along the muscle bundle 
lines was used to expose the femur. After all soft tissue had been cleaned away from the 
bone, a rigid fixation plate was attached to the anterolateral surface of the femur using 
two screws at each end (Figure 3.1). An 8 mm defect was then created in the diaphysis of 
the bone with an oscillating saw. Scaffolds were then wet with 300 mOsm/L saline 
solution and press fit into the defect site. Resorbable sutures and wound clips were used 
to close the incision site in two layers. Following recovery from anesthesia, animals were 
given subcutaneous buprenorphine injections every 8 hours for 72 hours for pain 
management. All animals recovered normal ambulation within 3 to 7 days following 
surgery. Wound clips were removed 14 days post-surgery.[6] Animals were housed in 
sterile housing, fed gamma-irradiated chow, and given sterile water.  
X-Ray and MicroCT Analysis 
 Healing of the bone defects was analyzed in vivo using both x-ray and microCT. 
Animals were anesthetized using Isofluorane during scanning. Each leg was scanned 
independently using a high resolution x-ray system (Faxitron X-Ray LLC, Lincolnshire, 
IL) at 4, 8, and 12 weeks. X-rays were used to determine whether the defects had bridged, 
defined by a continuous span of bone from one side of the defect to the other.[6]  
 Following x-ray scanning, each leg was also imaged using microCT at each time 
point (VivaCT scanner, Scanco Medical, Switzerland).  All scans were performed at a 38 
µm voxel resolution. The scanning region was defined as the space between the metal 
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attachment plates at either end of the defect. Scans were used to quantify mineral 
formation within the defect site. For analysis, only the central region of the defect was 
used. To locate this region, 2D slices were examined to find the end of the native cortical 
bone at both the proximal and distal ends of the defect. From these points, the center 
point and corresponding slice was calculated. The analysis region included this slice as 
well as 62 slices in either direction (125 total slices). Although the defect was 8 mm in 
length, this region only corresponds to the middle 4.75 mm. This reduction in the analysis 
region is necessary because of the angled alignment of the femurs with the axis of 
scanning. Due to space constraints in the microCT system, it is not possible to align the 
axis of the femur perfectly with the axis of the scanner.  Because only the quantity of new 
bone produced is desired, this angle decreases the assessable volume of interest (VOI) 
that excludes the native cortical bone (Figure 3.2). To determine the value used, each 
scan was examined to determine the effective distance between the native bone on either 
side of the defect at the angle the bone was scanned. The chosen value of 4.75 mm was 
the value of the scan that had the least distance between the ends of the native bone. That 
way, each scan could be evaluated with the same VOI without including native cortical 
bone. Scans were evaluated at a threshold of 100, a filter width of 1.2, and a filter support 
of 2 (n=10).[6, 11]  At 12 weeks post surgery, animals were sacrificed and limbs were 
harvested.  
Statistical Analysis 
 All statistical analysis was performed using GraphPad Prism (GraphPad Software, 
La Jolla, CA). For comparison between experimental groups and time points, an analysis 
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of variance was performed with Tukey post hoc analysis. Differences were considered 


















 One of the collagen scaffold treated limbs was omitted from evaluation due to 
fracturing of the femur around the screw holes at the proximal fixation site (n=9 for 
collagen group). Faxitron x-ray images were taken at 4, 8, and 12 weeks post surgery to 
monitor new bone formation. The resulting images for the AFS ECM, the MSC ECM, 
and the collagen coated scaffolds can be seen in Figure 3.3, 3.4, and 3.5 respectively. 
There was a lot of variance between the samples in each group, with some limbs showing 
little to no mineralization, while others showed significant amounts throughout the 
defect. The images were used to determine if the defects had bridged, defined by a 
continuous expanse of mineralized tissue from the proximal to distal end of the defect 
(Table 3.1). Based on this criterion, for the AFS synthesized ECM group, 2 defects had 
bridged at 4 weeks. However, only 1 additional defect bridged between 8 and 12 weeks, 
for a total of 3 bridged defects at 12 weeks (Figure 3.3). Similar results were seen with 
the MSC synthesized ECM: 1 defect bridged by 4 weeks, with an additional defect 
bridging between 8 and 12 weeks, for a total of 2 bridged defects (Figure 3.4). None of 
the defects bridged for the collagen coated scaffold group (Figure 3.5). 
 MicroCT imaging was used to measure the volume of mineralized matrix 
produced within the central 4.75 mm of the defect site for each limb. The results of this 
analysis can be seen in Figure 3.6. All groups contained around 5 mm3 of mineral within 
the analyzed VOI by 4 weeks. However, due to the large variance within each group, no 
significant differences were found either between the different groups or between the 
different time points. Although the difference was not significant, the average volume of 
mineral within the AFS ECM treated defects at 12 weeks was higher than at 4 weeks and 
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the other groups at 12 weeks (p=0.14 versus AFS ECM at 4 weeks, p=0.18 versus 
collagen scaffolds at 12 weeks). Analyses were also done to compare the ECM groups 
combined to the collagen coated scaffold group. However, no significant difference was 
found. Images representative of the average volume of mineralized matrix within the 
defect for each group at each time point can be seen in Figure 3.7.  
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Figure 3.3:    High resolution x-ray images of rat femoral segmental defects treated with 
AFS synthesized ECM. Images were taken at 4 weeks (left column), 8 weeks (center 
column), and 12 weeks (right column). Each row corresponds to the same limb at 

















Figure 3.4:    High resolution x-ray images of rat femoral segmental defects treated with 
MSC synthesized ECM. Images were taken at 4 weeks (left column), 8 weeks (center 
column), and 12 weeks (right column). Each row corresponds to the same limb at 


















Figure 3.5:    High resolution x-ray images of rat femoral segmental defects treated with 
collagen coated scaffolds. Images were taken at 4 weeks (left column), 8 weeks (center 
column), and 12 weeks (right column). Each row corresponds to the same limb at 
different time points. 
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Table 3.1:   Number of bridged defects for each group at each time point, as determined 
from x-ray images (bridged/total). 
 
Group Week 4 Week 8 Week 12 
AFS ECM 2/10 2/10 3/10 
MSC ECM 1/10 1/10 2/10 









Figure 3.6:    Mineral volume within the  central 4.75 mm of the a rat femoral segmental 
defect treated with either AFS cell synthesized ECM, MSC synthesized ECM or collagen 
















Figure 3.7:    In vivo microCT images of defects 4, 8, and 12 weeks post-implantation. 
Images are representative of the average value of mineralized matrix production for each 




 An 8 mm femoral segmental defect in a rat provides a challenging test bed for any 
potential bone tissue engineering therapy.  Success in this model is measured by bridging 
of the defect and the volume of mineralized matrix produced. Both ECM groups 
performed qualitatively better than the collagen control in terms of bridging. By 12 weeks 
in vivo, 30% of the AFS cell synthesized ECM treated defects, 20% of the MSC 
synthesized ECM treated defects, and 0% of the collagen scaffold treated defects had 
bridged. The AFS ECM group had the highest average mineralized matrix volume within 
the defect site at 12 weeks. However, due to the large variance within each group, this 
difference was not significant. These results suggest that while ECM did not induce more 
mineralized matrix production, it may affect the distribution of the matrix within the 
defect site improving the rate of bridging. 
 Other potential bone tissue engineering therapies have been tested in this 8 mm 
rat femoral segmental defect model. Rai et al utilized polycaprolactone-20% tricalcium 
phosphate scaffolds with platelet-rich plasma. With this treatment, bridging was observed 
in 5 out of 6 defects.[7]  Oest et al combined the growth factors BMP-2 and                   
transforming growth factor β3 (TGF-β3) with a poly(L-lactide-co-D,L-lactide) to treat the 
critically sized defect. This treatment resulted in bridging in 2 out of 6 defects. However, 
even in defects that did not bridge there was a large amount of mineralized matrix 
formation, with an average volume of over 31 mm3 at 16 weeks.[6] In comparison to 
these other results, while the ECM treatments were able to improve the rate of bridging, 
they fall short of other potential treatments in terms of both rate of bridging and 
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CHAPTER 4 
CONCLUSIONS AND FUTURE WORK 
 
Conclusions 
 The studies in this thesis were designed to assess the potential of stem cell 
synthesized extracellular matrix in bone tissue engineering applications. The overall goal 
was to quantify the osteoinductivity of the ECM produced by human AFS cells, compare 
it to that of MSCs, and assess its potential for use in bone tissue engineering therapies.  
To do this, a series of in vitro and in vivo experiments were designed and executed. First 
and foremost, the treatment of the ECM with freeze/thaw cycling and DNase was 
evaluated as a decellularization technique. Next, a series of 2D studies were performed to 
evaluate markers of osteogenic differentiation for MSCs reseeded on the acellular ECM. 
Similar studies were also performed to determine the effect of the ECM on the 
proliferation of the reseeded cells. 3D studies were then performed to determine the effect 
that the ECM had on reseeded cells in terms of attachment, proliferation, and mineralized 
matrix production in a more complex 3D environment. Finally, a rat femoral segmental 
defect model was used to evaluate the use of stem cell synthesized ECM as a bone tissue 
engineering therapy in vivo. It was hypothesized that the ECM produced by the human 
AFS cells would be osteoinductive, that the degree of osteoinductivity would be greater 
than that of the MSC-synthesized ECM due to the difference in the initial maturity levels 
of the cells, and that the mineralization and bridging of defects containing ECM 
constructs would be greater than that of the empty scaffolds. From the results of these 
studies, several conclusions can be made: 
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1. The ECM was successfully decellularized using freeze/thaw cycling and DNase 
treatment. Following decellularization, the DNA content within 3D PCL/ECM 
constructs was reduced to less than 10% of the predecellularization value. Any 
residual DNA in constructs was undetectable after 1 week in culture. Prior to 
decellularization, live/dead staining showed live cells saturating the scaffolds. 
After decellularization, no live cells could be found in any region of the construct.  
2. Reseeded MSCs were able to attach to and proliferate on both ECM types. 
Live/dead images showed live cells attached to all regions of the scaffold 
following reseeding. The attachment efficiency in 3D constructs fell between 25% 
and 50% for each ECM type and preculture period, significantly less than 
collagen coated scaffolds. However, the cells were able to proliferate rapidly on 
each ECM, matching the DNA content of the collagen coated scaffolds by 1 
week. DNA content in both 2D and 3D culture increased 5-fold over the first 
week of culture, illustrating the proliferative potential of the reseeded cells on the 
ECM.  
3. In 2D culture, reseeded cells seeded on ECM synthesized by each cell type 
showed evidence of osteogenic differentiation. The osteogenic markers were more 
prevalent with the MSC synthesized ECM, indicating that it may have superior 
osteoinductivity compared to AFS cell synthesized ECM in 2D culture. Both 
cultures showed increasing levels of calcium, consistent with mineralized matrix 
production by osteogenic cells. Calcium levels rose faster for cells cultured on 
MSC synthesized ECM. Additionally, MSCs cultured on MSC ECM saw a large 
peak in alkaline phosphatase activity at 1 week not seen in cells cultured on AFS 
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ECM. 
4. Cells cultured with both ECM and the osteoinductive factor dexamethasone 
experienced a synergistic effect in terms of osteogenic differentiation. These cells 
showed a more rapid increase in calcium content, and with the MSC ECM, a 
greater peak value of alkaline phosphatase activity at 1 week when compared to 
cells cultured without dexamethasone.  
5. In 3D in vitro culture, the presence of ECM increased the amount of mineralized 
matrix production.  The AFS ECM groups showed higher mineralized matrix 
volumes than the MSC ECM groups. For the AFS synthesized ECM, the longer 
preculture period of 8 weeks induced more mineral production than the 4 week 
period. These results suggest that in 3D, the AFS ECM has the potential to induce 
more mineralized matrix production, especially with longer preculture periods. 
6. Both ECM types contributed to healing of a critically sized rat femoral segmental 
defect in vivo. The rate of bridging was increased with the presence of ECM, with 
3 of 10 AFS ECM treated defects and 2 of 10 MSC ECM treated defects bridging, 
compared to 0 of 9 collagen coated scaffold treated defects. However, there was 
no significant difference in mineral volume between the ECM groups and 
collagen coated scaffolds at any time point. 
 Overall, acellular stem cell synthesized extracellular matrix possesses useful 
characteristics as a bone tissue engineering therapy. Cells were able to attach to and 
proliferate on the matrix. Osteoinductive effects were noted in both 2D and 3D in vitro 
culture. The MSC synthesized ECM appeared to have the greater osteoinductive effect in 
2D culture with the shorter 3 week preculture period, while the AFS synthesized matrix 
 80
had a greater effect in 3D with the longer 8 week preculture period. Both matrix types 
were able to aid in repair of a bone defect in a clinically relevant model, increasing the 
rate of bridging of the defects. However, the ECM failed to bridge the majority of the 
defects or induce mineralized matrix production beyond that seen with a collagen coated 
scaffold. When compared to the gold standard of BMP delivery, in vivo results suggest 
that the acellular stem cell synthesized extracellular matrix tested here is less effective as 
a bone tissue engineering therapy. However, the observed effects in vitro, particularly the 
noted synergistic effect, suggest that a therapy that stem cell synthesized ECM combined 
with another osteoinductive agent may have usefulness as a potential treatment for bone 
defects. 
Future Work 
 Improvements and further studies have been considered for evaluating the use of 
stem cell synthesized extracellular matrix as a bone tissue engineering therapy. A 
pronounced synergistic effect on osteogenic differentiation was noted when the ECM was 
combined with the osteoinductive agent dexamethasone. Similar results have been seen in 
other studies.[1, 2] These studies hypothesized that the effect may be due to the ECM 
providing an optimal microenvironment for osteogenic differentiation. The combined 
delivery of ECM with another osteoinductive agent, such as BMP-2, may be tested in a 
segmental defect model to determine if this synergistic effect is also observed in vivo. 
Another interesting approach for including additional osteoinductive agent would be to 
use gene therapy to cause the cells synthesizing the ECM construct to over express BMP-
2 in order to incorporate more of it within the ECM itself. If more bridging and 
mineralized matrix production are observed with the additional osteoinductive factors, it 
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is also important to perform mechanical testing on the healed defects to evaluate the 
restoration of function. 
 Further in vitro characterization of the ECM properties is important if the 
combined delivery of ECM and osteoinductive agent is successful. This will allow for 
fine-tuning of the therapy to produce the most desirable effect. One interesting 
observation to further elucidate would be that the MSC ECM was more osteoinductive in 
2D with a 3 week preculture period, while the AFS ECM appeared to be more 
osteoinductive in 3D with an 8 week preculture period. Two possible explanations for 
these observations are that either the ECMs from the different cell types perform 
differently in 2D versus 3D culture, or that they perform differently with different 
preculture periods. To examine this further, additional preculture time periods can be 
evaluated in the 3D model.  
 Once optimal preculture times are established, the composition of the ECM 
should be examined further. A bicinchoninic acid assay can be performed to measure the 
total protein content of the ECM and determine if it correlates to mineralized matrix 
production. Additionally, more complex biochemistry techniques can be used to 
determine the specific components of the ECM and their relative concentrations.  
 In addition to further examining the osteoinductive effects, other effects of the 
ECM on reseeded cells that would be beneficial to bone tissue engineering can be 
evaluated. In this thesis, the attachment and proliferation of reseeded cells on ECM was 
examined. It was observed that although fewer cells attached to the ECM than to collagen 
coated scaffolds, the cells on the ECM constructs proliferated more during the first week, 
resulting in a DNA content equal to that found in the collagen coated scaffolds after 1 
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week. However, the observed higher proliferation rate on the ECM constructs may have 
been due to saturation at the 1 week time point. To further examine this, additional 
evaluation time points can be added both before and after 1 week to approximate the rate 
of proliferation on the various scaffold types.  
 Finally, another potential beneficial effect of the ECM that was not examined in 
this study is improved angiogenesis. Other studies have found that the presence of MSC 
synthesized ECM resulted in increased blood vessel formation within an intramuscularly 
implanted scaffold when compared to an empty scaffold.[3] To evaluate the 
angiogenicity of the various ECM types, they could be implanted either subcutaneously 
or in a segmental defect. The blood vessel formation could then be analyzed through both 
histology and microCT by perfusing the animal with a contrast agent.  Further analysis of 
all of these effects would help fine-tune and improve the use of stem cell synthesized 
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